At a glance
- Originator Yamanouchi
- Class Analgesics; Antiulcers
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain; Peptic ulcer
Most Recent Events
- 20 Jun 2001 Discontinued-Preclinical for Pain in Japan (Unknown route)
- 31 Aug 1998 No-Development-Reported for Pain in Japan (Unknown route)
- 20 Aug 1996 Preclinical development for Pain in Japan (Unknown route)